In recent years the clinical significance, diagnostic methods, and therapy of anaerobic infections have been emphasized (1, 5, 7) . Because of the rare occurrence of aplastic anemia and the more common dose-related bone marrow suppression associated with the use of chloramphenicol (16) and the variable risk reported for clindamycin-associated colitis (6, 9, 15) , other antimicrobial agents for treatment of anaerobic infections are being sought (5) .
The macrolide antibiotics are active in vitro against anaerobic organisms. However, the activity of the most commonly used macrolide, erythromycin, is variable against most groups of anaerobes at concentrations achievable in the blood with oral therapy. Therefore, it is not recommended for use in anaerobic infections (7) . With parenteral erythromycin, higher concentrations can be achieved in blood, but the difficulties in using erythromycin parenterally have limited the role of erythromycin in anaerobic infections. An unanswered question is whether other macrolides would absorb better and be more efficacious, as was observed when lincomycin was modified to yield clindamycin (4) .
Josamycin is a macrolide antibiotic produced by Streptomyces narbonensis var. josamyceticus, which was isolated in Japan in 1964. In 1970, josamycin was marketed in Japan and later in Europe, where it has been used primarily for treatment of aerobic gram-positive infections (11) . Information regarding its activity against anaerobes is limited (11, 12 Table 2 . Although the differences were not marked, at potentially achievable concentrations josamycin was as active or more active than erythromycin against these organisms. Clindamycin was consistently more active at low concentrations, but the total number of organisms that were susceptible to higher concentrations of either clindamycin or josamycin (-3.12 ,ug/ml) was quite similar. Josamycin was either as active or more active than chloramphenicol but less active than penicillin against these gram-positive anaerobes (Table   2) .
Anaerobic gram-negative organisms. The Fig. 1 and 2) . Furthermore, josamycin is strikingly more active than penicillin against B. fragilis. Josamycin was inactive against Fusobacterium species (Fig. 3) . However, this group of organisms may have been unusually resistant. Less than one-half of the strains were susceptible to c0.39 Ag of penicillin per ml, although over 70% were susceptible to c0.097 ug of clindamycin per ml.
Aerobic gram-positive organisms. The activity ofjosamycin against gram-positive organisms is shown in five other patients with prosthetic valve endocarditis were susceptible to 0.39 4g or less of josamycin and clindamycin per ml, although they were markedly resistant to erythromycin.
DISCUSSION
Our studies show that josamycin was active against a variety of gram-positive aerobes. Strausbaugh and colleagues (12) recently reported similar median minimal inhibitory con- centrations ofjosamycin against Streptococcus pneumoniae, Streptococcus pyrogenes, and Staphylococcus aureus. Although josamycin was active against many gram-positive aerobes, it appeared to have no unique spectrum of activity.
Josamycin was quite active against the anaerobes, with the .exception of Fusobacterium species. A mean of 75% ofthe gram-positive and other gram-negative anaerobes was inhibited by 1.56 ug or less ofjosamycin per ml. At 3.12 ,ug or less of josamycin per ml, 100% of B. fragilis were susceptible. These results confirm, and expand, previous data that revealed that josamycin was active against anaerobes, although only a small number of strains were tested in these studies (11, 12) .
Presently, josamycin is available only as an oral preparation. After 750 mg of oral josamycin, mean peak serum concentrations range from 0.4 to 2.6 ,ug of josamycin per ml (2) . At concentrations of .3.12 ,ug of antibiotic per ml, the activities ofjosamycin and clindamycin are similar ( josamycin would limit its potential role in suspected clinical anaerobic infections. However, somewhat unexpectedly, a majority of the 14 strains of Fusobacterium species tested was also resistant to penicillin. Members of the genus Fusobacterium isolated in this study were not identified as to species. Therefore, from our data it cannot be determined if one or several particularFusobacterium species were more resistant than others to josamycin.
